Sichenzia Ross Friedman Ference LLP Represents ContraVir Pharmaceuticals, Inc. on $15 Million Public Offering of Common Stock and Warrants
Press Release – New York, NY – October 14, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP is pleased to announce that the Firm has represented ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, on an underwritten public offering of 5,000,000 shares of the Company’s common stock and warrants to purchase up to 3,000,000 shares of common stock at a combined public offering price of $3.00. ContraVir raised $15,000,000 in gross proceeds. Laidlaw & Company (UK) Ltd. was the sole book-running manager for the offering and Noble Financial Capital Markets acted as financial advisor.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Stephen A. Cohen.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)